/
BTMD
$1.70-$0.12 (-6.70%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$54.3M
30M shares
52-week range
$1.27 – $4.75
12% from low
Sector
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Exchange
NASDAQ
CS
Borrow rate
2.28%
Moderate
Price (6 mo)
Loading chart…
Change$-4.64
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $110.0M | $116.6M | $139.4M | $165.0M | $185.4M | $197.2M | $192.2M |
| Cost of revenue | $43.6M | $44.9M | $48.8M | $54.6M | $57.9M | $58.1M | $54.9M |
| Gross profit | $66.4M | $71.6M | $90.6M | $110.4M | $127.5M | $139.1M | $137.4M |
| Gross margin | 60.4% | 61.5% | 65.0% | 66.9% | 68.8% | 70.5% | 71.5% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $23.5M | $31.8M | $34.6M | −$60.7M | $28.7M | $31.6M | $35.6M |
| EBITDA | $24.3M | $32.9M | $36.0M | $8.0M | $39.5M | $15.6M | $52.2M |
| Net income | $21.3M | $29.2M | $32.6M | −$969.0K | $3.3M | $3.2M | $27.0M |
| Net margin | 19.4% | 25.0% | 23.4% | -0.6% | 1.8% | 1.6% | 14.1% |
| EPS (diluted) | 2.81 | 3.85 | -0.87 | 0.16 | 0.13 | 0.09 | 0.74 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $191M | $0.32 | $0.32–$0.32 | 1 |
| 2027 | $205M | $0.43 | $0.43–$0.43 | 1 |
| 2028 | $216M | $0.61 | $0.60–$0.62 | 1 |
| 2029 | $230M | $0.65 | $0.64–$0.66 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$9.75
Price
$1.70
Implied upside
+473%
Peer comparison
Biote Corp. Class A Common Stock
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
www.biote.com- Employees
- 223
- IPO / List date
- May 27, 2022
- HQ
- IRVING, TX
Held by traders on TradeandTell
No one on the platform currently holds BTMD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 265,916 | $359.0K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2007-06-01 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded BTMD yet.
